

### Technical Analysis



#### Analyst(s)

Greater China Research Team  
research-hk@uobkh.com

Tham Mun Hon, CFA

munhon.tham@uobkh.com  
+852 2236 6799

#### WuXi Biologics (2269 HK)

|                    |                     |
|--------------------|---------------------|
| Last price:        | HK\$50.70           |
| Support levels:    | HK\$47.80/HK\$44.40 |
| Resistance levels: | HK\$57.85/HK\$63.95 |

The price maintained its position above the resistance-turned-support zone, keeping the uptrend intact. Technical momentum reinforces this constructive outlook, as the RSI is above its neutral 50-midline. As long as buyers continue to defend this key support, path-of-least-resistance dynamics favour a sustained upward trajectory toward higher price targets.

**Average timeframe: Around two weeks.**



#### Hansoh Pharmaceutical (3692 HK)

|                    |                     |
|--------------------|---------------------|
| Last price:        | HK\$35.96           |
| Support levels:    | HK\$33.42/HK\$31.74 |
| Resistance levels: | HK\$40.12/HK\$43.94 |

The price successfully defended the big gap support zone, demonstrating strong demand-side momentum retention. The RSI operates securely above its neutral 50-midline. A decisive penetration above the immediate overhead swing peak at HK\$36.94 will clear any remaining resistance, opening the path for a sustained upward expansion toward higher primary target levels.

**Average timeframe: Around two weeks.**

**IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS**

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."